Cidara/Merck Phase 1 trial tests MK-1406 with Fluzone HD vaccine, recruiting
A Phase 1 trial sponsored by Cidara Therapeutics, a Merck & Co. subsidiary, is recruiting to study MK-1406 given alongside Fluzone High-Dose flu vaccine.
One update this week concerns a single Phase 1 trial from Cidara Therapeutics.
- This is a Phase 1, randomized trial sponsored by Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc.1 Its status is recruiting, with an actual start date of 2025-11-08 and an estimated primary completion date of 2026-12-31, and it plans to enroll 710 participants (estimated)1 in healthy adults. The trial will evaluate whether MK-1406 (formerly CD388) is safe to take with Fluzone® and whether it affects the immune response to Fluzone®, including safety and tolerability when administered with Fluzone® High-Dose (HD) compared to Fluzone® HD with placebo.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.